Bivalirudin, abciximab and clopidogrel in modern PCI: interpretation and experience from King’s College Hospital

Br J Cardiol (Acute Interv Cardiol) 2006;13:AIC 5–AIC 8 Leave a comment
Click any image to enlarge
Authors:

Platelet inhibition is a prerequisite for successful percutaneous coronary interventions (PCI). Aspirin was the first antiplatelet agent with proven benefit in ST-elevation infarction (STEMI) in the era of thrombolysis, significantly lowering death rate and the recurrence of ischaemic events.








Advertisement

For UK healthcare professionals only


THERE ARE CURRENTLY NO COMMENTS FOR THIS ARTICLE - LEAVE A COMMENT